CN1152022C - α-取代的嘧啶-硫代烷基和烷基醚化合物 - Google Patents
α-取代的嘧啶-硫代烷基和烷基醚化合物 Download PDFInfo
- Publication number
- CN1152022C CN1152022C CNB961937912A CN96193791A CN1152022C CN 1152022 C CN1152022 C CN 1152022C CN B961937912 A CNB961937912 A CN B961937912A CN 96193791 A CN96193791 A CN 96193791A CN 1152022 C CN1152022 C CN 1152022C
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- amino
- chloro
- ethyl
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ATCRIOJPQXDFNY-ZETCQYMHSA-N C[C@@H](c1ncc2[o]ccc2c1)Sc1nc(Cl)cc(N)n1 Chemical compound C[C@@H](c1ncc2[o]ccc2c1)Sc1nc(Cl)cc(N)n1 ATCRIOJPQXDFNY-ZETCQYMHSA-N 0.000 description 2
- 0 CC(*)(c1ncc2[o]ccc2c1)S(C)c1nc(Cl)cc(N)n1 Chemical compound CC(*)(c1ncc2[o]ccc2c1)S(C)c1nc(Cl)cc(N)n1 0.000 description 1
- LNSDMSXRCRPSMV-UHFFFAOYSA-N CC(C)(c(nc1)cc2c1[o]cc2C)Sc1nc(Cl)cc(N)n1 Chemical compound CC(C)(c(nc1)cc2c1[o]cc2C)Sc1nc(Cl)cc(N)n1 LNSDMSXRCRPSMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43670895A | 1995-05-08 | 1995-05-08 | |
| US08/436,708 | 1995-05-08 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200410032589XA Division CN1535958A (zh) | 1995-05-08 | 1996-05-03 | α-取代的嘧啶-硫代烷基和烷基醚化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1183773A CN1183773A (zh) | 1998-06-03 |
| CN1152022C true CN1152022C (zh) | 2004-06-02 |
Family
ID=23733510
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB961937912A Expired - Fee Related CN1152022C (zh) | 1995-05-08 | 1996-05-03 | α-取代的嘧啶-硫代烷基和烷基醚化合物 |
| CNA200410032589XA Pending CN1535958A (zh) | 1995-05-08 | 1996-05-03 | α-取代的嘧啶-硫代烷基和烷基醚化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200410032589XA Pending CN1535958A (zh) | 1995-05-08 | 1996-05-03 | α-取代的嘧啶-硫代烷基和烷基醚化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6043248A (enExample) |
| EP (2) | EP1449835A3 (enExample) |
| JP (1) | JPH11507017A (enExample) |
| KR (1) | KR100445498B1 (enExample) |
| CN (2) | CN1152022C (enExample) |
| AT (1) | ATE275550T1 (enExample) |
| AU (1) | AU712404B2 (enExample) |
| BR (1) | BR9608265A (enExample) |
| CA (1) | CA2216099C (enExample) |
| CZ (1) | CZ293135B6 (enExample) |
| DE (1) | DE69633332T2 (enExample) |
| ES (1) | ES2227586T3 (enExample) |
| GE (1) | GEP20002297B (enExample) |
| HU (1) | HUP9801995A3 (enExample) |
| IL (1) | IL118075A0 (enExample) |
| MX (1) | MX9708582A (enExample) |
| NO (1) | NO310287B1 (enExample) |
| NZ (1) | NZ307089A (enExample) |
| PL (1) | PL323240A1 (enExample) |
| PT (1) | PT824524E (enExample) |
| RU (1) | RU2167155C2 (enExample) |
| SK (1) | SK150297A3 (enExample) |
| TW (1) | TW450962B (enExample) |
| UA (1) | UA56992C2 (enExample) |
| WO (1) | WO1996035678A1 (enExample) |
| ZA (1) | ZA963281B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526378A (ja) * | 1997-09-25 | 2002-08-20 | ファルマシア・アンド・アップジョン・カンパニー | チオアルキル−アルファ−置換ピリミジン化合物 |
| US6111111A (en) * | 1997-10-23 | 2000-08-29 | Kuraray Co., Ltd. | Intermediates for producing pyridine derivatives |
| BR9913831A (pt) | 1998-09-17 | 2001-05-29 | Bristol Myers Squibb Co | Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação |
| US7358254B2 (en) | 2001-07-13 | 2008-04-15 | Bristol-Myers Squibb Company | Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| CA2376951A1 (en) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Src kinase inhibitor compounds |
| CA2376957A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
| ES2755273T3 (es) * | 2004-12-03 | 2020-04-22 | Merck Sharp & Dohme | Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación |
| SI1858861T1 (sl) * | 2005-03-04 | 2010-10-29 | Tibotec Pharm Ltd | 2-(4-cianofenil)-6-hidroksilaminopirimidini, ki inhibirajo HIV |
| US7923056B2 (en) | 2007-06-01 | 2011-04-12 | Illinois Tool Works Inc. | Method and apparatus for dispensing material on a substrate |
| AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
| CN101638391B (zh) * | 2009-08-21 | 2011-04-27 | 山东大学 | 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3h-嘧啶-4-酮类衍生物及其制备方法与应用 |
| US9226970B2 (en) | 2010-02-22 | 2016-01-05 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
| EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
| SG186820A1 (en) * | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht- 2 -ylacetic acid derivatives to treat aids |
| ES2667425T3 (es) | 2011-06-10 | 2018-05-10 | Oregon Health & Science University | Glucoproteínas y vectores recombinantes de CMV |
| AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| KR101360587B1 (ko) * | 2012-11-01 | 2014-03-10 | 현대자동차주식회사 | 스마트 도어 언록 시스템 |
| US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| NZ739226A (en) | 2015-07-22 | 2022-11-25 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| KR20220101083A (ko) * | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
| EP4093198A4 (en) * | 2020-01-20 | 2024-01-24 | Agrematch Ltd. | Compositions for crop protection |
| CN114057707A (zh) * | 2021-11-24 | 2022-02-18 | 上海应用技术大学 | 一种n-4-吲哚基-2-呋喃甲酰胺化合物的制备方法 |
| CN118715205A (zh) * | 2022-01-12 | 2024-09-27 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性相关的病症的化合物和组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2295560A (en) * | 1941-06-18 | 1942-09-15 | Gen Electric | Pyrimidine derivatives |
| GB744867A (en) * | 1952-10-29 | 1956-02-15 | American Cyanamid Co | Improvements relating to 2-substituted-mercapto-4-amino-6-disubstituted-aminopyrimidines and acid addition salts thereof |
| US3940394A (en) * | 1972-03-31 | 1976-02-24 | Santilli Arthur A | 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides |
| US3940240A (en) * | 1974-07-11 | 1976-02-24 | Ina Seito Co., Ltd. | Baking method and kiln for tile |
| ATE25255T1 (de) * | 1983-05-05 | 1987-02-15 | Heumann Ludwig & Co Gmbh | Pyrimidin-thioalkylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel. |
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPS62209062A (ja) * | 1986-03-10 | 1987-09-14 | Yamanouchi Pharmaceut Co Ltd | ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物 |
| JPH07107056B2 (ja) * | 1987-01-30 | 1995-11-15 | 日清製粉株式会社 | ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤 |
| WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| HU203736B (en) * | 1989-04-06 | 1991-09-30 | Gyogyszerkutato Intezet | Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them |
| ATE142621T1 (de) * | 1989-12-28 | 1996-09-15 | Upjohn Co | Diaromatische substituierte verbindungen gegen den aids-virus |
| US5668136A (en) * | 1990-09-25 | 1997-09-16 | Eisai Co., Ltd. | Trisubstituted benzene derivatives, composition and methods of treatment |
| CA2109934C (en) * | 1991-07-03 | 2002-12-10 | Donna Lee Romero | Substituted indoles as anti-aids pharmaceuticals |
| GB2266716A (en) * | 1992-05-05 | 1993-11-10 | Merck & Co Inc | Inhibitors of HIV reverse transcriptase |
| JP3077046B2 (ja) * | 1992-08-31 | 2000-08-14 | 久光製薬株式会社 | 新規なキナゾリン誘導体 |
| AU7636894A (en) * | 1993-09-17 | 1995-04-03 | Upjohn Company, The | Substituted tetronic acids useful for treating hiv and other retroviruses |
| KR100354309B1 (ko) * | 1993-11-12 | 2003-01-06 | 파마시아 앤드 업존 캄파니 | 피리미딘-티오알킬및알킬에테르화합물 |
| AU2395095A (en) * | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
| SK281683B6 (sk) * | 1994-07-20 | 2001-06-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tiopyridylové zlúčeniny a ich použitie |
-
1996
- 1996-03-05 UA UA97125800A patent/UA56992C2/uk unknown
- 1996-04-24 ZA ZA9603281A patent/ZA963281B/xx unknown
- 1996-04-29 IL IL11807596A patent/IL118075A0/xx unknown
- 1996-05-03 CN CNB961937912A patent/CN1152022C/zh not_active Expired - Fee Related
- 1996-05-03 MX MX9708582A patent/MX9708582A/es not_active IP Right Cessation
- 1996-05-03 NZ NZ307089A patent/NZ307089A/xx unknown
- 1996-05-03 AU AU56353/96A patent/AU712404B2/en not_active Ceased
- 1996-05-03 CN CNA200410032589XA patent/CN1535958A/zh active Pending
- 1996-05-03 CA CA002216099A patent/CA2216099C/en not_active Expired - Fee Related
- 1996-05-03 RU RU97120116/04A patent/RU2167155C2/ru not_active IP Right Cessation
- 1996-05-03 PT PT96913306T patent/PT824524E/pt unknown
- 1996-05-03 KR KR1019970707927A patent/KR100445498B1/ko not_active Expired - Fee Related
- 1996-05-03 JP JP8534120A patent/JPH11507017A/ja not_active Withdrawn
- 1996-05-03 ES ES96913306T patent/ES2227586T3/es not_active Expired - Lifetime
- 1996-05-03 PL PL96323240A patent/PL323240A1/xx unknown
- 1996-05-03 BR BR9608265A patent/BR9608265A/pt not_active Application Discontinuation
- 1996-05-03 EP EP04010159A patent/EP1449835A3/en not_active Withdrawn
- 1996-05-03 WO PCT/US1996/006119 patent/WO1996035678A1/en not_active Ceased
- 1996-05-03 HU HU9801995A patent/HUP9801995A3/hu unknown
- 1996-05-03 SK SK1502-97A patent/SK150297A3/sk unknown
- 1996-05-03 AT AT96913306T patent/ATE275550T1/de not_active IP Right Cessation
- 1996-05-03 DE DE69633332T patent/DE69633332T2/de not_active Expired - Fee Related
- 1996-05-03 GE GEAP19964013A patent/GEP20002297B/en unknown
- 1996-05-03 US US08/945,153 patent/US6043248A/en not_active Expired - Fee Related
- 1996-05-03 EP EP96913306A patent/EP0824524B1/en not_active Expired - Lifetime
- 1996-05-03 CZ CZ19973491A patent/CZ293135B6/cs not_active IP Right Cessation
- 1996-05-07 TW TW085105432A patent/TW450962B/zh not_active IP Right Cessation
-
1997
- 1997-11-07 NO NO19975129A patent/NO310287B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1152022C (zh) | α-取代的嘧啶-硫代烷基和烷基醚化合物 | |
| CN1211373C (zh) | 用作抗肿瘤药的2,4－二(杂－)芳基氨基(－氧基)－5－取代的嘧啶 | |
| CN1024793C (zh) | 制备氨基嘧啶衍生物的方法 | |
| CN1656073A (zh) | 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物 | |
| CN1675225A (zh) | 大环嘧啶化合物、其制备方法以及作为药物的应用 | |
| CN1524079A (zh) | 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用 | |
| CN1662236A (zh) | 组蛋白脱乙酰基转移酶抑制剂 | |
| CN1302301A (zh) | 用作细胞增殖抑制剂的二环嘧啶及二环3,4－二氢嘧啶化合物 | |
| CN1142817A (zh) | 1n-烷基-n-芳基嘧啶胺及其衍生物 | |
| CN1255133A (zh) | 1,5－二氢－吡唑并[3,4－d]－嘧啶酮衍生物 | |
| CN1701073A (zh) | 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶 | |
| CN101044137A (zh) | 作为plk抑制剂的2,4－二（氨基苯基）嘧啶 | |
| CN1867553A (zh) | 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途 | |
| CN1071917A (zh) | 用作人类免疫缺陷病毒逆转录酶拮抗剂的喹唑啉衍生物 | |
| CN1561216A (zh) | 新化合物 | |
| CN1993360A (zh) | 作为激酶抑制剂的缩合的吡啶类 | |
| CN1416420A (zh) | 1,2,3,4－四氢异喹啉的衍生物 | |
| CN1863774A (zh) | 用作蛋白激酶抑制剂的化合物和组合物 | |
| CN1351497A (zh) | 用作山梨醇脱氢酶抑制剂的氨基嘧啶类化合物 | |
| CN1633419A (zh) | Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用 | |
| CN1451005A (zh) | 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶 | |
| CN1930160A (zh) | Hiv整合酶抑制剂 | |
| CN1688580A (zh) | 作为磷酸二酯酶4抑制剂的2－三氟甲基－6－氨基嘌呤衍生物 | |
| CN1106663A (zh) | 噻吩并嘧啶衍生物及其制备方法和用途 | |
| CN101031570A (zh) | Vegf受体和hgf受体信号的抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |